Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00239330 |
The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.
Condition | Intervention | Phase |
---|---|---|
Hypercholesteremia |
Drug: Rosuvastatin Drug: Atorvastatin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Randomised, Multi-Centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia |
Estimated Enrollment: | 824 |
Study Start Date: | June 2003 |
Study Completion Date: | February 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
Research Site | |
Brussels, Belgium | |
Research Site | |
Antwerpen, Belgium | |
Research Site | |
Arlon, Belgium | |
Research Site | |
Assebroek, Belgium | |
Research Site | |
Ath, Belgium | |
Research Site | |
Aye, Belgium | |
Research Site | |
Bastogne, Belgium | |
Research Site | |
Baudour, Belgium | |
Research Site | |
Borgerhout, Belgium | |
Research Site | |
Bornem, Belgium | |
Research Site | |
Bouge, Belgium | |
Research Site | |
Brugge, Belgium | |
Research Site | |
Charleroi, Belgium | |
Research Site | |
Sint-Agatha-Berchem, Belgium | |
Research Site | |
Frameries, Belgium | |
Research Site | |
Gent, Belgium | |
Research Site | |
Hasselt, Belgium | |
Research Site | |
Havré, Belgium | |
Research Site | |
Kortenberg, Belgium | |
Research Site | |
Leuven, Belgium | |
Research Site | |
Mol, Belgium | |
Research Site | |
Namur, Belgium | |
Research Site | |
Oostende, Belgium | |
Research Site | |
Roeselare, Belgium | |
Research Site | |
Schoten, Belgium | |
Research Site | |
Dendermonde, Belgium |
Study Director: | Guy Vandenhoven, MD | AstraZeneca NV/SA |
Study ID Numbers: | D3560L00011, DISCOVERY |
Study First Received: | October 13, 2005 |
Last Updated: | March 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00239330 History of Changes |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
high blood cholesterol levels |
Antimetabolites Rosuvastatin Metabolic Diseases Hyperlipidemias Antilipemic Agents Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolic Disorder Hypercholesterolemia Atorvastatin Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Pharmacologic Actions Rosuvastatin Therapeutic Uses Hypercholesterolemia Dyslipidemias Atorvastatin Lipid Metabolism Disorders |